New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
04:55 EDTAET, AET, AET, SGYP, SGYP, SGYP, SYK, SYK, SYK, EW, EW, EW, CCXI, CCXI, CCXI, INFI, INFI, INFI, QSII, QSII, QSII, SIAL, SIAL, SIALCitigroup to host a conference
Global Healthcare Conference is being held in New York on February 25-27.
News For EW;CCXI;INFI;QSII;SIAL;AET;SGYP;SYK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 24, 2014
08:37 EDTEWEdwards Lifesciences price target raised to $132 from $100 at Stifel
Stifel increased its price target on Edwards as the firm believes that the company's Q3 results were "outstanding." The firm thinks the TAVR market has a number of very visible and positive global rivers, while the stock has a number of potential positive catalysts. The firm keeps a Buy rating on the shares.
October 23, 2014
16:21 EDTEWEdwards Lifesciences raises FY14 EPS $3.33-$3.39, consensus $3.30
Sees FY 14 revenue higher than previous $2.05B-$2.25B, consensus $2.24B.
16:19 EDTEWEdwards Lifesciences sees Q4 EPS 89c-95c, consensus 95c
Sees Q4 revenue $575M-$615M, consensus $586.91M.
16:15 EDTEWEdwards Lifesciences reports Q3 EPS 80c, consensus 73c
Reports Q3 revenue $607.4M, consensus $546.32M.
15:30 EDTEWNotable companies reporting after market close
Subscribe for More Information
13:40 EDTAETWal-Mart's Sam's Club offering services to small businesses
Subscribe for More Information
12:10 EDTSYKMOKO Social Media acquires 80% stake in Tagroom.com
Subscribe for More Information
07:16 EDTSIALSigma-Aldrich sees Q4 EPS 5c below prior view
Subscribe for More Information
07:15 EDTSIALSigma-Aldrich says no longer providing annual guidance, citing merger
Subscribe for More Information
07:13 EDTSIALSigma-Aldrich reports Q3 adjusted EPS $1.06, consensus $1.06
Subscribe for More Information
05:47 EDTQSIIQuality Systems reports Q2 EPS 13c, consensus 14c
Reports Q2 revenue $120.5M, consensus $119.48M. During the quarter, the company’s pipeline grew to $161.8M, improving for the eighth consecutive quarter. At quarter-end, the company’s liquidity position was strong, with $123.5M of cash and investments. Steven T. Plochocki, president and CEO, stated, “During the Q2, we saw marked improvement across all fronts within the organization. The significant progress we are making is having a cumulative effect, which is creating positive momentum in our business and our results. We continue to realize benefits from the initiatives we have put into place over the past year, including the restructuring of our functional organizations, the cross selling of our products and services and the release of new solutions that cater to the evolving healthcare marketplace. Revenue Cycle Management, population health and interoperability are all among the key areas that are impacting the company’s sales and marketing efforts, in terms of both net new deals as well as cross selling into our growing client base. All of this strengthens our position as we head into the second half of this fiscal year.”
October 22, 2014
15:37 EDTSIALNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Comcast (CMCSA), consensus 71c; Union Pacific (UNP), consensus $1.52; 3M (MMM), consensus $1.96; AbbVie (ABBV), consensus 77c; Celgene (CELG), consensus 95c; Eli Lilly (LLY), consensus 67c; Occidental Petroleum (OXY), consensus $1.57; Caterpillar (CAT), consensus $1.36; Alexion Pharmaceuticals (ALXN), consensus $1.16; Precision Castparts (PCP), consensus $3.32; Raytheon (RTN), consensus $1.60; American Electric Power (AEP), consensus $1.02; Southwest Airlines (LUV), consensus 53c; Lorillard (LO), consensus 90c; T. Rowe Price (TROW), consensus $1.15; Mead Johnson (MJN), consensus 91c; Zimmer Holdings (ZMH), consensus $1.30; Nucor (NUE), consensus 73c; Nielsen (NLSN), consensus 65c; Prologis (PLD), consensus 46c; Sigma-Aldrich (SIAL), consensus $1.06; Under Armour (UA), consensus 40c; EQT (EQT), consensus 56c; Dr Pepper Snapple (DPS), consensus 88c; Cameron International (CAM), consensus $1.10; Coca-Cola Enterprises (CCE), consensus 89c; Quest Diagnostics (DGX), consensus $1.08; CMS Energy (CMS), consensus 41c; Airgas (ARG), consensus $1.29; PulteGroup (PHM), consensus 36c; Diamond Offshore (DO), consensus 79c; Bemis (BMS), consensus 67c.
October 21, 2014
08:39 EDTCCXIChemoCentryx reports CCX507 well tolerated, effective in Phase I study
Subscribe for More Information
06:06 EDTSGYPSynergy Pharm' presents positive data from phase 2b study of plecanatide
Synergy Pharmaceuticals announced the presentation of results from a phase 2b dose-ranging study assessing plecanatide’s safety and efficacy in 424 adult patients with irritable bowel syndrome with constipation. Data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period. Notably, patients taking 3.0 and 9.0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C.
05:19 EDTQSIIQuality Systems dental division announces strategic partnership with Patterson
Subscribe for More Information
October 20, 2014
08:37 EDTCCXIChemoCentryx releases Phase III SHIELD 4 clinical results
ChemoCentryx reported data from the Phase III SHIELD 4 clinical trial in Crohn's disease with vercirnon, an inhibitor of the chemokine receptor known as CCR9. Data showed that patients experienced improved response and remission rates when taking a higher dose of vercirnon. There was no evidence of higher gastrointestinal, hepatic, or cardiovascular adverse events with the twice daily group compared to the once daily group. Thomas J. Schall, Ph.D., president and CEO stated, "These SHIELD 4 data are consistent with our earlier positive PROTECT-1 study data. As with PROTECT-1, the data indicate that vercirnon is safe and well tolerated in patients with Crohn's disease, and there is a dose-dependent improvement in symptoms in the observed patient population in SHIELD 4. The Phase III drug CCX282/vercirnon, in addition to our second-generation, Phase II-ready CCR9 inhibitor, CCX507, provide a strong complement of drugs in our CCR9 program for which we intend to find a strategic partner."
07:12 EDTSYKCongress of Neurological Surgeons to hold annual meeting
Subscribe for More Information
07:04 EDTINFIInfinity Pharmaceuticals coverage resumed with a Hold at Stifel
October 17, 2014
07:45 EDTSYKStryker price target lowered to $84 from $88 at Canaccord
Subscribe for More Information
05:20 EDTQSII NextGen Healthcare, InterSystems demonstrate cross-vendor interoperability
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use